{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:24:38Z","timestamp":1789601078102,"version":"build-2803163510"},"reference-count":309,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.ejmech.2014.08.013","type":"journal-article","created":{"date-parts":[[2014,8,7]],"date-time":"2014-08-07T16:48:36Z","timestamp":1407430116000},"page":"535-568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Some molecular targets for antihyperlipidemic drug research"],"prefix":"10.1016","volume":"85","author":[{"given":"Nikhilesh","family":"Arya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mangesh D.","family":"Kharjul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chamanlal J.","family":"Shishoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishnu N.","family":"Thakare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishor S.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2014.08.013_bib1","series-title":"Current Clinical Practice: Essential Practice Guidelines in Primary Care","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-1-59745-313-4_2","article-title":"Hyperlipidemia","author":"Cohen","year":"2007"},{"issue":"5","key":"10.1016\/j.ejmech.2014.08.013_bib2","first-page":"393","article-title":"Population-level changes to promote cardiovascular health","volume":"14","author":"J\u00f8rgensen","year":"2013","journal-title":"G.\u00a0Ital. Cardiol. (Rome)"},{"key":"10.1016\/j.ejmech.2014.08.013_bib3","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/mnfr.201100392","article-title":"Beneficial effects of mangiferin on hyperlipidemia in high-fat-fed hamsters","volume":"55","author":"Guo","year":"2011","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.ejmech.2014.08.013_bib4","unstructured":"Website: http:\/\/www.americanheart.org\/statistics. (American Heart Association: 2001 Heart and Stroke Statistical Update. DallasTexas: American Heart Association, 2000)."},{"key":"10.1016\/j.ejmech.2014.08.013_bib5","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1016\/j.bmc.2007.04.031","article-title":"The biology and chemistry of hyperlipidemia","volume":"15","author":"Jain","year":"2007","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2014.08.013_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3476(98)70167-2","article-title":"Heart healthy diets for all children: no longer controversial","volume":"133","author":"Jacobson","year":"1998","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.ejmech.2014.08.013_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1876506801205010013","article-title":"LDL as a cause of atherosclerosis","volume":"5","author":"Tomkin","year":"2012","journal-title":"J.\u00a0Atheroscler. Thromb."},{"key":"10.1016\/j.ejmech.2014.08.013_bib8","unstructured":"Website: http:\/\/lipidsonline.com (This site has been designed and developed by CCIT \u2013 the Center for Collaborative and Interactive Technologies at Baylor college of medicine in Houston, Texas for educational sources in atherosclerosis)."},{"key":"10.1016\/j.ejmech.2014.08.013_bib9","unstructured":"Website: http:\/\/theheartinst.com\/patienteducation\/?id=31611&lang=English&db=hlt& ebscoType\u00a0=static&widgetTitle=Cardiac+Procedures (This homepage gives information on how the cardiovascular system works, the diseases that cause problems to it, ways doctors can repair it and steps one can take to keep it working well for a lifetime)."},{"issue":"7","key":"10.1016\/j.ejmech.2014.08.013_bib10","first-page":"336","article-title":"Dr D.S. Fredrickson: founding father of the field of lipidology","volume":"54","author":"Wong","year":"2012","journal-title":"B.\u00a0C. Med. J."},{"key":"10.1016\/j.ejmech.2014.08.013_bib11","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0022-3476(03)00186-0","article-title":"Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial","volume":"143","author":"McCrindle","year":"2003","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.ejmech.2014.08.013_bib12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0021-9150(99)00150-1","article-title":"Remodelling of high density lipoproteins by plasma factors","volume":"145","author":"Rye","year":"1999","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejmech.2014.08.013_bib13","unstructured":"Website: http:\/\/www.preventive-cardiology.com\/lipoprotein%20a.htm (This website belongs to Preventive Cardiology of Victoria, developed for prevent Atherosclerosis which is without question the most common cause of death in the developed world)."},{"key":"10.1016\/j.ejmech.2014.08.013_bib14","volume":"vol. 14","year":"1984"},{"key":"10.1016\/j.ejmech.2014.08.013_bib15","series-title":"Lipoprotein Lipase from Milk \u2013 the Model Enzyme in Lipoprotein Lipase Research","first-page":"15","author":"Olivecrona","year":"1987"},{"key":"10.1016\/j.ejmech.2014.08.013_bib16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1126\/science.3513311","article-title":"A\u00a0receptor-mediated pathway for cholesterol homeostasis","volume":"232","author":"Brown","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2014.08.013_bib17","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0009-8981(74)90250-2","article-title":"Isolation and analysis of human plasma lipoproteins accumulating postrandial in an intermediate density fraction (d 1.006\u20131.019 g-ml)","volume":"54","author":"Fellin","year":"1974","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ejmech.2014.08.013_bib18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0021-9150(88)90304-8","article-title":"Interactions of triiodothyronine, insulin and dexamethasone on the binding of human LDL to rat hepatocytes in monolayer culture","volume":"71","author":"Salter","year":"1988","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejmech.2014.08.013_bib19","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1161\/01.CIR.100.6.576","article-title":"Reverse cholesterol transport and atherosclerosis regression","volume":"100","author":"Spady","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ejmech.2014.08.013_bib20","unstructured":"Website: http:\/\/www.sigmaaldrich.com\/life-science\/metabolomics\/enzyme-explorer\/learning-center\/plasma-blood-protein\/lipoprotein-function.html (This homepage gives information on classification of lipoproteins)."},{"key":"10.1016\/j.ejmech.2014.08.013_bib21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/330132a0","article-title":"cDNA sequence of human apolipoprotein(a) is homologous to plasminogen","volume":"330","author":"McLean","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2014.08.013_bib22","first-page":"14","article-title":"Recent trends in hyperlipoproteinemias and its pharmacotherapy","volume":"27","author":"Ghatak","year":"1995","journal-title":"Indian J. Pharmacol."},{"key":"10.1016\/j.ejmech.2014.08.013_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0025-7125(16)30174-2","article-title":"Lipoprotein metabolism and its relationship to atherosclerosis","volume":"78","author":"Ginsberg","year":"1994","journal-title":"Med. Clin. N. Am."},{"key":"10.1016\/j.ejmech.2014.08.013_bib24","unstructured":"Website: www.hvif.com (This home page belongs to The Heart and Vascular Institute of Florida, describes new frontier of cardiovascular care and treatment through advances in nuclear medicine, cutting edge technology and research and the development of preventive and educational services)."},{"key":"10.1016\/j.ejmech.2014.08.013_bib25","unstructured":"Website: http:\/\/www.clinicalcardiology.org\/supplements\/CC26S1\/supplement_1_03. pdf (Clinical Cardiology provides a forum for the coordination of clinical research in cardiology and cardiovascular surgery)."},{"key":"10.1016\/j.ejmech.2014.08.013_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-74-1-1","article-title":"Serum cholesterol, lipoproteins and the risk of coronary heart disease. The Framingham study","volume":"74","author":"Kannel","year":"1971","journal-title":"Ann. Intern. Med."},{"issue":"Suppl.\u00a0A","key":"10.1016\/j.ejmech.2014.08.013_bib27","first-page":"A20","article-title":"Lipoprotein metabolism","volume":"19","author":"Beisiegel","year":"1998","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejmech.2014.08.013_bib28","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1146\/annurev.bi.49.070180.003315","article-title":"Lipolytic enzymes and plasma lipoprotein metabolism","volume":"49","author":"Nilsson","year":"1980","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejmech.2014.08.013_bib29","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/oxfordjournals.jbchem.a134000","article-title":"Mechanism of inhibition of hepatic triglyceride lipase from human postheparin plasma by apolipoproteins A-I and A-II","volume":"92","author":"Kubo","year":"1982","journal-title":"J.\u00a0Biochem."},{"issue":"2","key":"10.1016\/j.ejmech.2014.08.013_bib30","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00041433-200004000-00008","article-title":"Structure and function of lecithin cholesterol acyl transferase: new insights from structural predictions and animal models","volume":"11","author":"Peelman","year":"2000","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.ejmech.2014.08.013_bib31","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/01.ATV.0000121505.88326.d2","article-title":"High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease","volume":"24","author":"Brewer","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejmech.2014.08.013_bib32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00041433-199908000-00008","article-title":"The assembly and secretion of apolipoprotein B-containing lipoproteins","volume":"10","author":"Olofsson","year":"1999","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.ejmech.2014.08.013_bib33","doi-asserted-by":"crossref","first-page":"20747","DOI":"10.1016\/S0021-9258(19)36846-2","article-title":"Molecular cloning and functional expression of human acyl-coenzyme A: cholesterol acyltransferase c-DNA in mutant Chinese hamster ovary cells","volume":"268","author":"Chang","year":"1993","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2014.08.013_bib34","unstructured":"Website: http:\/\/www.learn.ppdictionary.com\/exercise_and_lipoproteins5.htm (This home page of the journal of undergraduate biological studies gives an overview on lipoproteins)."},{"key":"10.1016\/j.ejmech.2014.08.013_bib35","first-page":"328","article-title":"Beyond LDL-cholesterol","volume":"9","author":"Kostner","year":"2002","journal-title":"J.\u00a0Kardiol."},{"issue":"25","key":"10.1016\/j.ejmech.2014.08.013_bib36","first-page":"1","article-title":"Regulation of reverse cholesterol transport \u2013 a comprehensive appraisal of available studies","volume":"9","author":"Annema","year":"2012","journal-title":"Nutr. Metab. (Lond)"},{"key":"10.1016\/j.ejmech.2014.08.013_bib37","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2174\/138955710791185037","article-title":"Current drug targets for antihyperlipidemic therapy","volume":"10","author":"Jain","year":"2010","journal-title":"Mini-rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2014.08.013_bib38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrm2336","article-title":"Cellular cholesterol trafficking and compartmentalization","volume":"9","author":"Ikonen","year":"2008","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"3","key":"10.1016\/j.ejmech.2014.08.013_bib39","doi-asserted-by":"crossref","first-page":"e33962","DOI":"10.1371\/journal.pone.0033962","article-title":"CUP-1 is a novel protein involved in dietary cholesterol uptake in Caenorhabditis elegans","volume":"7","author":"Valdes","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.ejmech.2014.08.013_bib40a","first-page":"91","article-title":"Ezetimibe: a proven cholesterol absorption inhibitor drug","volume":"46","author":"Kathiravan","year":"2009","journal-title":"Indian Drugs"},{"key":"10.1016\/j.ejmech.2014.08.013_bib40b","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0021-9150(00)00456-1","article-title":"Intestinal absorption of triglyceride and cholesterol. Dietary and pharmacological inhibition to reduce cardiovascular risk","volume":"151","author":"Ros","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejmech.2014.08.013_bib41","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ejmech.2014.01.002","article-title":"The chemistry and biological potential of azetidin-2-ones","volume":"74","author":"Arya","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2014.08.013_bib42","doi-asserted-by":"crossref","first-page":"6929","DOI":"10.1016\/j.bmcl.2010.09.138","article-title":"Spiroimidazolidinone NPC1L1 inhibitors. Part 2: structure-activity studies and in\u00a0vivo efficacy","volume":"20","author":"Howell","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2014.08.013_bib43","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.chembiol.2012.05.018","article-title":"Visualization of lipid metabolism in the zebrafish intestine reveals a relationship between NPC1L1-mediated cholesterol uptake and dietary fatty acid","volume":"19","author":"Walters","year":"2012","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2014.08.013_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0018722","article-title":"The structure of the NPC1L1 N-terminal domain in a closed conformation","volume":"6","author":"Kwon","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.ejmech.2014.08.013_bib45","doi-asserted-by":"crossref","first-page":"7397","DOI":"10.1074\/jbc.M110.178368","article-title":"Molecular characterization of the NPC1L1 variants identified from cholesterol low absorbers","volume":"286","author":"Wang","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2014.08.013_bib46","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1073\/pnas.1014434108","article-title":"Flotillins play an essential role in Niemann-Pick C1-like 1-mediated cholesterol uptake","volume":"108","author":"Ge","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2014.08.013_bib47","doi-asserted-by":"crossref","first-page":"E172","DOI":"10.25011\/cim.v34i3.15190","article-title":"Increased NPC1L1 and serum cholesterol in a chronic rejection rat","volume":"34","author":"Zhu","year":"2011","journal-title":"Clin. Invest. Med."},{"issue":"2","key":"10.1016\/j.ejmech.2014.08.013_bib48","doi-asserted-by":"crossref","first-page":"G203","DOI":"10.1152\/ajpgi.00288.2012","article-title":"D-Glucose modulates intestinal Niemann-Pick C1-like 1 (NPC1L1) gene expression via transcriptional regulation","volume":"304","author":"Malhotra","year":"2013","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.ejmech.2014.08.013_bib49","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.bbalip.2011.05.013","article-title":"Ezetimibe restores biliary cholesterol excretion in mice expressing Niemann-Pick C1-Like 1 only in liver","volume":"1811","author":"Tang","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"issue":"23","key":"10.1016\/j.ejmech.2014.08.013_bib50","doi-asserted-by":"crossref","first-page":"8132","DOI":"10.1073\/pnas.0500269102","article-title":"The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)","volume":"102","author":"Garcia-Calvo","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2014.08.013_bib51","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1126\/science.294.5548.1866","article-title":"Nuclear receptors and lipid physiology: opening the X-files","volume":"294","author":"Chawala","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2014.08.013_bib52","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1172\/JCI10370","article-title":"Peroxisome proliferator-activated receptor \u03b3 ligands inhibit development of atherosclerosis in LDL receptor-deficient mice","volume":"106","author":"Li","year":"2000","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ejmech.2014.08.013_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/753917","article-title":"Atherogenic \u03c9-6 lipids modulate PPAR-EGR-1 crosstalk in vascular cells","volume":"2011","author":"Fei","year":"2011","journal-title":"PPAR Res."},{"key":"10.1016\/j.ejmech.2014.08.013_bib54","doi-asserted-by":"crossref","first-page":"5876","DOI":"10.1016\/j.bmcl.2011.07.095","article-title":"Ursolic acid is a PPAR-\u03b1 agonist that regulates hepatic lipid metabolism","volume":"21","author":"Jia","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2014.08.013_bib55","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.atherosclerosis.2010.10.033","article-title":"Evaluation of anti-atherosclerotic activities of PPAR-\u03b1, PPAR-\u03b3, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F(1)B hamsters","volume":"214","author":"Srivastava","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejmech.2014.08.013_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1478-1336-3-3","article-title":"Gene expression profiling of potential peroxisome proliferator-activated receptor (PPAR) target genes in human hepatoblastoma cell lines inducibly expressing different PPAR isoforms","volume":"3","author":"Tachibana","year":"2005","journal-title":"Nucl. Recept."},{"key":"10.1016\/j.ejmech.2014.08.013_bib57","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1100\/tsw.2010.213","article-title":"The nuclear hormone receptor PPAR\u03b3 as a therapeutic target in major diseases","volume":"10","author":"Schmidt","year":"2010","journal-title":"Sci. World J."},{"key":"10.1016\/j.ejmech.2014.08.013_bib58a","first-page":"46","article-title":"Bioinformatics analysis on regulatory mechanism of peroxisome proliferator-activated receptor-\u00ce\u00b3 gene on lipid metabolism","volume":"18","author":"Guo","year":"2011","journal-title":"J.\u00a0Northeast Agric. Univ. Engl. Ed."},{"key":"10.1016\/j.ejmech.2014.08.013_bib58b","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.prp.2010.01.010","article-title":"Increased expression of peroxisomeproliferator-activated receptor (PPAR)-alpha and PPAR-gammain human atherosclerosis","volume":"206","author":"Sueyoshi","year":"2010","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.ejmech.2014.08.013_bib59","doi-asserted-by":"crossref","first-page":"48051","DOI":"10.1074\/jbc.M206966200","article-title":"Reduction of atherosclerosis by the peroxisome proliferator-activated receptor \u03b1 agonist fenofibrate in mice","volume":"277","author":"Duez","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2014.08.013_bib60","unstructured":"Website: http:\/\/www.medscape.org\/viewarticle\/561751 (This site gives information on treating hyperglycemia and dyslipidemia in people with diabetes: achieving optimal treatment targets)."},{"key":"10.1016\/j.ejmech.2014.08.013_bib61","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.bmcl.2009.11.115","article-title":"Novel phospholipid analogues of pan-PPAR activator tetradecylthioacetic acid are more PPAR\u03b1 selective","volume":"20","author":"Alcor","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2014.08.013_bib62","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.bbalip.2012.11.012","article-title":"Cyanidin is an agonistic ligand for PPAR-alpha reducing hepatic lipid","volume":"1831","author":"Jia","year":"2013","journal-title":"BBA Mol. Cell Biol. Lipids"},{"issue":"13","key":"10.1016\/j.ejmech.2014.08.013_bib63","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1021\/jm0502135","article-title":"Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha\/gamma dual agonists with potent antihyperglycemic and lipid modulating activity","volume":"48","author":"Shi","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.08.013_bib64","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/toxsci\/kfi118","article-title":"Evaluation of polycyclic aromatic hydrocarbons in the activation of early growth response-1 and peroxisome proliferator activated receptors","volume":"85","author":"Kim","year":"2005","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.ejmech.2014.08.013_bib65","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/0165-6147(91)90546-5","article-title":"Therapeutic potential of ACAT inhibitors as lipid lowering and anti-atherosclerotic agents","volume":"12","author":"Sliskovic","year":"1991","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2014.08.013_bib66a","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00041433-199908000-00005","article-title":"Intestinal cholesterol absorption","volume":"10","author":"Dawson","year":"1999","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.ejmech.2014.08.013_bib66b","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0002-9440(10)64723-2","article-title":"Localization of human acyl-coenzyme A: cholesterol acyltransferase-1 (ACAT-1) in macrophages and in various tissues","volume":"156","author":"Sakashita","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejmech.2014.08.013_bib67","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1152\/ajpendo.90926.2008","article-title":"Acyl-coenzyme A: cholesterol acyltransferases","volume":"297","author":"Chang","year":"2009","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2014.08.013_bib68","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1161\/ATVBAHA.111.223552","article-title":"Pyripyropene A, an ACAT-2-selective inhibitor, attenuates hypercholesterolemia and atherosclerosis in murine models of hyperlipidemia","volume":"31","author":"Ohshiro","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"10","key":"10.1016\/j.ejmech.2014.08.013_bib69","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1016\/j.bmcl.2010.03.101","article-title":"First identification of xanthone sulfonamides as potent ACAT inhibitors","volume":"20","author":"Hu","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2014.08.013_bib70","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1161\/01.ATV.20.1.70","article-title":"The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits","volume":"20","author":"Bocan","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejmech.2014.08.013_bib71","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1124\/jpet.103.050526","article-title":"Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor","volume":"306","author":"Shai","year":"2003","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejmech.2014.08.013_bib72","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.atherosclerosis.2010.08.048","article-title":"A\u00a0selective ACAT-1 inhibitor, K-604, stimulates collagen production in cultured smooth muscle cells and alters plaque phenotype in apolipoprotein E-knockout mice","volume":"213","author":"Yoshinaka","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejmech.2014.08.013_bib73","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.cbi.2010.05.006","article-title":"Fucoxanthin supplementation improves plasma and hepatic lipid metabolism and blood glucose concentration in high-fat fed C57BL\/6N mice","volume":"186","author":"Woo","year":"2010","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2014.08.013_bib74","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/S0022-2275(20)32360-9","article-title":"Differential expression of ACAT1 and ACAT2 among cells within liver, intestine, kidney, and adrenal of nonhuman primates","volume":"41","author":"Lee","year":"2000","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ejmech.2014.08.013_bib75","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2014.08.013_bib76","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1073\/pnas.82.3.901","article-title":"Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10","volume":"82","author":"Folkers","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2014.08.013_bib77","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1073\/pnas.90.1.45","article-title":"Autoxidation of lipids and antioxidation by alpha-tocopherol and ubiquinol in homogeneous solution and in aqueous dispersions of lipids: unrecognized consequences of lipid particle size as exemplified by oxidation of human low density lipoprotein","volume":"90","author":"Ingold","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2014.08.013_bib78","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1016\/0098-2997(94)90037-X","article-title":"Treatment of essential hypertension with coenzyme Q10","volume":"15","author":"Langsjoen","year":"1994","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.ejmech.2014.08.013_bib79","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0891-5849(00)00296-3","article-title":"The effect of \u03b1-tocopherol on the oxidative cleavage of \u03b2-carotene","volume":"29","author":"Witting","year":"2000","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejmech.2014.08.013_bib80","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0098-2997(94)90026-4","article-title":"Usefulness of coenzyme Q10 in clinical cardiology: a long-term study","volume":"15","author":"Langsjoen","year":"1994","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.ejmech.2014.08.013_bib81","unstructured":"Website: http:\/\/www.mbschachter.com\/coenzyme_q10.htm (This site gives information on combining innovative ideas in nutrition and holistic health with the latest developments in mainstream medicine)."},{"issue":"11","key":"10.1016\/j.ejmech.2014.08.013_bib82","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/iub.388","article-title":"The reduced form of coenzyme Q10 mediates distinct effects on cholesterol metabolism at the transcriptional and metabolite level in SAMP1 mice","volume":"62","author":"Schmelzer","year":"2010","journal-title":"IUBMB Life"},{"key":"10.1016\/j.ejmech.2014.08.013_bib83","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.reprotox.2009.11.009","article-title":"Cadmium-induced lipid peroxidation and changes in antioxidant defense system in the rat testes: protective role of coenzyme Q(10) and vitamin E","volume":"29","author":"Ognjanovi\u0107","year":"2010","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.ejmech.2014.08.013_bib84","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.nutres.2010.01.007","article-title":"Atorvastatin increases blood ratios of vitamin E\/low-density lipoprotein cholesterol and coenzyme Q10\/low-density lipoprotein cholesterol in hypercholesterolemic patients","volume":"30","author":"Liu","year":"2010","journal-title":"Nutr. Res."},{"key":"10.1016\/j.ejmech.2014.08.013_bib85","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejphar.2011.04.061","article-title":"Combined atorvastatin and coenzyme Q10 improve the left ventricular function in isoproterenol-induced heart failure in rat","volume":"666","author":"Garjani","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2014.08.013_bib86","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.atherosclerosis.2011.02.050","article-title":"Rosuvastatin combined with regular exercise preserves coenzyme Q10 levels associated with a significant increase in high-density lipoprotein cholesterol in patients with coronary artery disease","volume":"217","author":"Toyama","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejmech.2014.08.013_bib87","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.nut.2011.06.004","article-title":"Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with coronary artery disease","volume":"28","author":"Lee","year":"2012","journal-title":"Nutrition"},{"key":"10.1016\/j.ejmech.2014.08.013_bib88","first-page":"33","article-title":"Antioxidant effects of quercetin and coenzyme Q10 in mini organ cultures of human nasal mucosa cells","volume":"29","author":"Reiter","year":"2009","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejmech.2014.08.013_bib89","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/biof.5520090225","article-title":"Coenzyme Q10 treatment in serious heart failure","volume":"9","author":"Munkhlom","year":"1999","journal-title":"BioFactors"},{"key":"10.1016\/j.ejmech.2014.08.013_bib90a","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0003-9861(69)90532-3","article-title":"Tricarballylate and hydroxycitrate: substrate and inhibitor of ATP: citrate oxaloacetate lyase","volume":"135","author":"Watson","year":"1969","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejmech.2014.08.013_bib90b","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1432-1033.1973.tb03038.x","article-title":"Inhibition of enzymes which interact with citrate by (-)hydroxycitrate and 1,2,3-tricarboxybenzene","volume":"38","author":"Cheema","year":"1973","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ejmech.2014.08.013_bib91","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0076-6879(81)72038-X","article-title":"Hydroxycitrate","volume":"72","author":"Lowestein","year":"1981","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.ejmech.2014.08.013_bib92","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1042\/bj3340113","article-title":"The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076","volume":"334","author":"Pearce","year":"1998","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2014.08.013_bib93","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1194\/jlr.M003335","article-title":"Deficiency in hepatic ATP-citrate lyase affects VLDL-triglyceride mobilization and liver fatty acid composition in mice","volume":"51","author":"Wang","year":"2010","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ejmech.2014.08.013_bib94","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.molcel.2013.07.002","article-title":"Acetylation stabilizes ATP-citrate lyase to promote lipid biosynthesis and tumor growth","volume":"51","author":"Lin","year":"2013","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2014.08.013_bib95","doi-asserted-by":"crossref","first-page":"27418","DOI":"10.1074\/jbc.M109.078667","article-title":"Identification of the citrate-binding site of human ATP-citrate lyase using X-ray crystallography","volume":"285","author":"Sun","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2014.08.013_bib96","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1194\/jlr.D900008-JLR200","article-title":"A\u00a0novel direct homogeneous assay for ATP citrate lyase","volume":"50","author":"Ma","year":"2009","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ejmech.2014.08.013_bib97","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1152\/physrev.00022.2005","article-title":"Mechanisms for cellular cholesterol transport: defects and human disease","volume":"86","author":"Ikonen","year":"2006","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2014.08.013_bib98a","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/00001573-200307000-00008","article-title":"Emerging importance of HDL cholesterol in developing high-risk coronary plaques in acute coronary syndromes","volume":"18","author":"Viles-Gonzalez","year":"2003","journal-title":"Curr. Opin. Cardiol."},{"key":"10.1016\/j.ejmech.2014.08.013_bib98b","unstructured":"Website: http:\/\/www.sjhg.org\/wp-content\/uploads\/2012\/10\/heartbeat81_julaug2003.pdf (This site gives information on emerging importance of HDL-C)."},{"issue":"12","key":"10.1016\/j.ejmech.2014.08.013_bib99","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.jacc.2008.03.016","article-title":"Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches","volume":"51","author":"deGoma","year":"2008","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"7897","key":"10.1016\/j.ejmech.2014.08.013_bib100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0140-6736(75)92376-4","article-title":"Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease","volume":"1","author":"Miller","year":"1975","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2014.08.013_bib101","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1161\/01.ATV.12.8.972","article-title":"Normal postprandial lipemia in men with low plasma HDL concentrations","volume":"12","author":"Cohen","year":"1992","journal-title":"Arterioscler. Thromb."},{"key":"10.1016\/j.ejmech.2014.08.013_bib102","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0022-2275(20)37757-9","article-title":"Effects of fat ingestion on high density lipoprotein profiles in human sera","volume":"25","author":"Groot","year":"1984","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ejmech.2014.08.013_bib103","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S0022-2275(20)38090-1","article-title":"Effects of dietary carbohydrate and fat on plasma lipoproteins and apolipoproteins C-II and C-III in healthy men","volume":"231","author":"Kashyap","year":"1982","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ejmech.2014.08.013_bib104","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0021-9258(19)68346-8","article-title":"Changes in the distribution and composition of plasma high density lipoproteins after ingestion of fat","volume":"257","author":"Tall","year":"1982","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2014.08.013_bib105","doi-asserted-by":"crossref","first-page":"E492","DOI":"10.1152\/ajpendo.1991.260.3.E492","article-title":"Postprandial decrease in HDL cholesterol and HDL apo A-I in normal subjects in relation to triglyceride metabolism","volume":"260","author":"DeBruin","year":"1991","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2014.08.013_bib106","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/00041433-199810000-00009","article-title":"High density associated enzymes: their role in vascular biology","volume":"9","author":"Navab","year":"1998","journal-title":"Curr. Opin. Lipidol."},{"issue":"23","key":"10.1016\/j.ejmech.2014.08.013_bib107","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1016\/j.jacc.2010.02.035","article-title":"RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in\u00a0vitro and in\u00a0vivo","volume":"55","author":"Bailey","year":"2010","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.ejmech.2014.08.013_bib108","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1161\/ATVBAHA.108.179275","article-title":"High-density lipoprotein-based contrast agents for multimodal imaging of atherosclerosis","volume":"30","author":"Skajaa","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejmech.2014.08.013_bib109","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1194\/jlr.R001610","article-title":"The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?","volume":"51","author":"Vergeer","year":"2010","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ejmech.2014.08.013_bib110","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1093\/eurheartj\/eht343","article-title":"High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality","volume":"34","author":"Silbernagel","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejmech.2014.08.013_bib111","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1161\/CIRCULATIONAHA.112.000889","article-title":"HDL's protein cargo: friend or foe in cardioprotection?","volume":"127","author":"Heinecke","year":"2013","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ejmech.2014.08.013_bib112","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/ki.2009.177","article-title":"In\u00a0vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide","volume":"76","author":"Vaziri","year":"2009","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejmech.2014.08.013_bib113","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/S0022-2275(20)32526-8","article-title":"Evidence that microsomal triglyceride transfer protein is limiting in the production of apolipoprotein B-containing lipoproteins in hepatic cells","volume":"39","author":"Jamil","year":"1998","journal-title":"J.\u00a0Lipid Res."},{"issue":"Suppl.\u00a0l","key":"10.1016\/j.ejmech.2014.08.013_bib114","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1017\/S000711450000088X","article-title":"Obesity, insulin resistance and diabetes \u2013 a worldwide epidemic","volume":"83","author":"Seidell","year":"2000","journal-title":"Br. J. Nutr."},{"key":"10.1016\/j.ejmech.2014.08.013_bib115","doi-asserted-by":"crossref","first-page":"28J","DOI":"10.1016\/S0002-9149(99)00355-0","article-title":"Insulin resistance and lipid metabolism","volume":"84","author":"Howard","year":"1999","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ejmech.2014.08.013_bib116","doi-asserted-by":"crossref","first-page":"812","DOI":"10.2337\/diacare.22.5.812","article-title":"Apolipoprotein(B) identifies dyslipidemic phenotypes associated with cardiovascular risk in normocholesterolemic type 2 diabetic patients","volume":"22","author":"Wagner","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejmech.2014.08.013_bib117","first-page":"685","article-title":"Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study","volume":"30","author":"Duvillard","year":"2000","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.ejmech.2014.08.013_bib118","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S0022-2275(20)32400-7","article-title":"Microsomal triglyceride transfer protein expression during mouse development","volume":"41","author":"Shelton","year":"2000","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ejmech.2014.08.013_bib119","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S1388-1981(00)00049-4","article-title":"Progress towards understanding the role of microsomal triglyceride transfer protein in apolipoprotein-B lipoprotein assembly","volume":"1486","author":"Gordon","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"issue":"6","key":"10.1016\/j.ejmech.2014.08.013_bib120","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0009-9120(03)00038-9","article-title":"Emergence of the metabolic syndrome in childhood: an epidemiological overview and mechanistic link to dyslipidemia","volume":"36","author":"Avramoglu","year":"2003","journal-title":"Clin. Biochem."},{"issue":"14","key":"10.1016\/j.ejmech.2014.08.013_bib121","first-page":"1","article-title":"Multiple functions of microsomal triglyceride transfer protein","volume":"9","author":"Hussain","year":"2012","journal-title":"Nutr. Metabol."},{"key":"10.1016\/j.ejmech.2014.08.013_bib122","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1194\/jlr.M005744","article-title":"An intrinsic gut leptin-melanocortin pathway modulates intestinal microsomal triglyceride transfer protein and lipid absorption","volume":"51","author":"Iqbal","year":"2010","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ejmech.2014.08.013_bib123","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.bbrc.2010.05.114","article-title":"Mechanisms underlying different responses of plasma triglyceride to high-fat diets in hamsters and mice: roles of hepatic MTP and triglyceride secretion","volume":"398","author":"Gao","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2014.08.013_bib124","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia","volume":"356","author":"Cuchel","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2014.08.013_bib125a","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1161\/01.ATV.0000054658.91146.64","article-title":"Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis","volume":"23","author":"Barter","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejmech.2014.08.013_bib125b","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1161\/01.CIR.0000015857.31889.7B","article-title":"Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study","volume":"105","author":"deGrooth","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ejmech.2014.08.013_bib126","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0009-9120(97)00098-2","article-title":"Reverse cholesterol transport-a review of the process and its clinical implications","volume":"30","author":"Hill","year":"1997","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ejmech.2014.08.013_bib127","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/eurheartj\/ehp399","article-title":"Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors","volume":"31","author":"Chapman","year":"2010","journal-title":"Eur. Heart J."},{"issue":"18","key":"10.1016\/j.ejmech.2014.08.013_bib128","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1007\/s00018-010-0418-3","article-title":"Cholesteryl ester transfer protein and its inhibition","volume":"67","author":"Weber","year":"2010","journal-title":"Cell. Mol. Life Sci."},{"issue":"19","key":"10.1016\/j.ejmech.2014.08.013_bib129","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/jama.2011.1649","article-title":"Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial","volume":"306","author":"Nicholls","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2014.08.013_bib130","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1111\/j.1755-5922.2010.00201.x","article-title":"Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion","volume":"29","author":"Kappelle","year":"2011","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.ejmech.2014.08.013_bib131","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1194\/jlr.M018069","article-title":"Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure","volume":"52","author":"Cao","year":"2011","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ejmech.2014.08.013_bib132","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1517\/13543784.2010.488219","article-title":"Dalcetrapib: a review of phase II data","volume":"19","author":"Robinson","year":"2010","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2014.08.013_bib133","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5837\/bjc.2012.024","article-title":"Cholesteryl ester transfer protein (CETP) inhibitors","volume":"19","author":"Durrington","year":"2012","journal-title":"Br. J. Cardiol."},{"key":"10.1016\/j.ejmech.2014.08.013_bib134a","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/BF02536247","article-title":"Cholesteryl ester transfer protein inhibition by PD 140195","volume":"29","author":"Bisgaier","year":"1994","journal-title":"Lipids"},{"key":"10.1016\/j.ejmech.2014.08.013_bib134b","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1021\/jm000337b","article-title":"Discovery of chiral N,N-disubstituted trifluoro-3-amino-2-propanols as potent inhibitors of cholesteryl ester transfer protein","volume":"43","author":"Durley","year":"2000","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.08.013_bib135","doi-asserted-by":"crossref","first-page":"13870","DOI":"10.1021\/bi001356q","article-title":"Stereospecific inhibition of CETP by chiral N,N-disubstituted trifluoro-3-amino-2-propanols","volume":"39","author":"Connolly","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2014.08.013_bib136","doi-asserted-by":"crossref","first-page":"37321","DOI":"10.1074\/jbc.M112.380063","article-title":"Crystal structures of CETP in complex with inhibitors","volume":"287","author":"Liu","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2014.08.013_bib137","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0022-2275(20)31511-X","article-title":"Influence of dietary fatty acid composition on the relationship between CETP activity and plasma lipoproteins in monkeys","volume":"42","author":"Fusegawa","year":"2001","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ejmech.2014.08.013_bib138","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1172\/JCI112940","article-title":"Accelerated transfer of cholesteryl esters in dyslipidemic plasma. Role of cholesteryl ester transfer protein","volume":"79","author":"Tall","year":"1987","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ejmech.2014.08.013_bib139","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1161\/01.ATV.4.1.49","article-title":"Isolation and characterization of human plasma lipid transfer proteins","volume":"4","author":"Albers","year":"1984","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.ejmech.2014.08.013_bib140","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/S0022-2275(20)37862-7","article-title":"Measurement of apolipoprotein A-I concentration in nonhuman primate serum by enzyme-linked immunosorbent assay (ELISA)","volume":"24","author":"Koritnik","year":"1983","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ejmech.2014.08.013_bib141","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/01.CIR.0000053730.47739.3C","article-title":"Clinical application of C-reactive protein for cardiovascular disease detection and prevention","volume":"107","author":"Ridker","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ejmech.2014.08.013_bib142","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis \u2013 an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2014.08.013_bib143a","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.2337\/diacare.28.9.2312","article-title":"Inflammation, atherosclerosis, and aspects of insulin action","volume":"28","author":"Bloomgarden","year":"2005","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.ejmech.2014.08.013_bib143b","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.jacc.2007.06.012","article-title":"C-reactive protein gene polymorphisms, C-reactive protein blood levels, and cardiovascular disease risk","volume":"50","author":"Hage","year":"2007","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.ejmech.2014.08.013_bib144","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jacc.2013.05.016","article-title":"High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?","volume":"62","author":"Yousuf","year":"2013","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.ejmech.2014.08.013_bib145","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/01.CIR.0000136819.93989.E1","article-title":"Increase in serum amyloid a evoked by dietary cholesterol is associated with increased atherosclerosis in mice","volume":"110","author":"Lewis","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ejmech.2014.08.013_bib146","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.acvd.2009.10.003","article-title":"Efficacy of simvastatin or ezetimibe on tissue factor, von Willebrand's factor and C-reactive protein in patients with hypercholesterolaemia","volume":"103","author":"Kostakou","year":"2010","journal-title":"Arch. Cardiovasc. Dis."},{"key":"10.1016\/j.ejmech.2014.08.013_bib147","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jacc.2013.02.098","article-title":"Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian cardiac outcomes trial lipid-lowering arm","volume":"62","author":"Sever","year":"2013","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"11","key":"10.1016\/j.ejmech.2014.08.013_bib148","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.amjcard.2011.01.050","article-title":"Reaching C-reactive protein and low-density lipoprotein cholesterol goals in dyslipidemic patients (from the Lipid Treatment Assessment Project [L-TAP] 2)","volume":"107","author":"Chiang","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ejmech.2014.08.013_bib149","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.lfs.2013.02.018","article-title":"Effects of ezetimibe on markers of synthesis and absorption of cholesterol in high-risk patients with elevated C-reactive protein","volume":"92","author":"Barbosa","year":"2013","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.ejmech.2014.08.013_bib150","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.atherosclerosis.2013.01.021","article-title":"Lutein supplementation reduces plasma lipid peroxidation and C-reactive protein in healthy nonsmokers","volume":"227","author":"Wang","year":"2013","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.ejmech.2014.08.013_bib151","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.atherosclerosis.2012.11.012","article-title":"Effects of atorvastatin on human C-reactive protein metabolism","volume":"226","author":"Thongtang","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejmech.2014.08.013_bib152","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0969-2126(99)80023-9","article-title":"The physiological structure of human C-reactive protein and its complex with phosphocholine","volume":"7","author":"Thompsom","year":"1999","journal-title":"Struct. Fold. Des."},{"issue":"7","key":"10.1016\/j.ejmech.2014.08.013_bib153","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/clinchem\/46.7.934","article-title":"Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population","volume":"46","author":"Hutchinson","year":"2000","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ejmech.2014.08.013_bib154","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1042\/bst0320134","article-title":"Lipid oxidation in atherogenesis: an overview","volume":"32","author":"Jessup","year":"2004","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.ejmech.2014.08.013_bib155","unstructured":"Website: http:\/\/www.qiagen.com\/products\/genes%20and%20pathways\/research-%20-portals\/cardiovascular%20disease\/ (This site belongs to home page of Qiagen which gives information on atherosclerosis)."},{"key":"10.1016\/j.ejmech.2014.08.013_bib156","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1161\/01.CIR.100.11.1148","article-title":"Novel inflammatory markers of coronary risk: theory versus practice","volume":"100","author":"Libby","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ejmech.2014.08.013_bib157","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1016\/S0960-894X(03)00490-6","article-title":"Novel coumarin derivatives of heterocyclic compounds as lipid-lowering agents","volume":"13","author":"Madhavan","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2014.08.013_bib158","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1021\/jm991039l","article-title":"Hypocholesterolemic and hypolipidemic activity of some novel morpholine derivatives with antioxidant activity","volume":"43","author":"Chrysselis","year":"2000","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.08.013_bib159","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1016\/j.bbamem.2011.08.011","article-title":"The natural antioxidant rosmarinic acid spontaneously penetrates membranes to inhibit lipid peroxidation in situ","volume":"1808","author":"Fadel","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2014.08.013_bib160","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1016\/j.febslet.2012.09.025","article-title":"Do antioxidants impair signalling by reactive oxygen species and lipid oxidation products?","volume":"586","author":"Niki","year":"2012","journal-title":"FEBS Lett."},{"issue":"1\u20133","key":"10.1016\/j.ejmech.2014.08.013_bib161","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.regpep.2010.02.008","article-title":"Ghrelin promotes antioxidant enzyme activity and reduces lipid peroxidation in the rat ovary","volume":"162","author":"Kheradmand","year":"2010","journal-title":"Regul. Pept."},{"key":"10.1016\/j.ejmech.2014.08.013_bib162","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ejphar.2011.06.053","article-title":"Protective effects of vanillic acid on electrocardiogram, lipid peroxidation, antioxidants, proinflammatory markers and histopathology in isoproterenol induced cardiotoxic rats","volume":"668","author":"Prince","year":"2011","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejmech.2014.08.013_bib163","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.chemphyslip.2010.10.002","article-title":"Ranking antioxidants based on their effect on human serum lipids peroxidation","volume":"164","author":"Pinchuk","year":"2011","journal-title":"Chem. Phys. Lipids"},{"issue":"1","key":"10.1016\/j.ejmech.2014.08.013_bib164","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.foodres.2012.01.002","article-title":"Target release rate of antioxidants to extend induction period of lipid oxidation","volume":"47","author":"Zhu","year":"2012","journal-title":"Food Res. Int."},{"issue":"1","key":"10.1016\/j.ejmech.2014.08.013_bib165","first-page":"79","article-title":"Evaluation of in\u00a0vitro antioxidant activity of5H-dibenz[b,f]azepine and its analogues","volume":"21","author":"Honnaiah","year":"2010","journal-title":"J.\u00a0Phys. Sci."},{"key":"10.1016\/j.ejmech.2014.08.013_bib166","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/75651","article-title":"Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking DGAT","volume":"25","author":"Smith","year":"2000","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2014.08.013_bib167","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1034\/j.1399-0004.2002.620109.x","article-title":"DGAT1 promoter polymorphism associated with alterations in body mass index, high density lipoprotein levels and blood pressure in Turkish women","volume":"62","author":"Ludwig","year":"2002","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ejmech.2014.08.013_bib168","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1194\/jlr.R800018-JLR200","article-title":"Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis","volume":"49","author":"Yen","year":"2008","journal-title":"J.\u00a0Lipid Res."},{"issue":"32","key":"10.1016\/j.ejmech.2014.08.013_bib169","doi-asserted-by":"crossref","first-page":"28235","DOI":"10.1074\/jbc.M111.256008","article-title":"Murine diacylglycerol acyltransferase-2 (DGAT2) can catalyze triacylglycerol synthesis and promote lipid droplet formation independent of its localization to the endoplasmic reticulum","volume":"286","author":"McFie","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2014.08.013_bib170","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.bbalip.2011.08.010","article-title":"Lack of acyl-CoA: diacylglycerol acyltransferase 1 reduces intestinal cholesterol absorption and attenuates atherosclerosis in apolipoprotein E knockout mice","volume":"1811","author":"Chandak","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2014.08.013_bib171","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejphar.2010.03.056","article-title":"In\u00a0vivo efficacy of acyl CoA: diacylglycerol acyltransferase (DGAT) 1 inhibition in rodent models of postprandial hyperlipidemia","volume":"637","author":"King","year":"2010","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejmech.2014.08.013_bib172","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1021\/ml3000512","article-title":"Intestinally targeted diacylglycerol acyltransferase 1 (DGAT1) inhibitors robustly suppress postprandial triglycerides","volume":"3","author":"Serrano-Wu","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"issue":"8","key":"10.1016\/j.ejmech.2014.08.013_bib173","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.bbalip.2013.04.013","article-title":"Intestinal acyl-CoA: diacylglycerol acyltransferase 2 overexpression enhances postprandial triglyceridemic response and exacerbates high fat diet-induced hepatic triacylglycerol storage","volume":"1831","author":"Uchida","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2014.08.013_bib174","doi-asserted-by":"crossref","first-page":"41838","DOI":"10.1074\/jbc.M111.245456","article-title":"Targeting acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases","volume":"286","author":"Cao","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2014.08.013_bib175","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1021\/jm00055a012","article-title":"32-Methyl-32-oxylanosterols: dual-action inhibitors of cholesterol biosynthesis","volume":"36","author":"Frye","year":"1993","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.08.013_bib176","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1006\/bbrc.2001.2008","article-title":"Membrane-bound enzymes of cholesterol synthesis from lanosterol","volume":"292","author":"Gaylor","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2014.08.013_bib177","unstructured":"Website: http:\/\/lipidlibrary.aocs.org\/Lipids\/cholest\/index.htm (This website belongs to AOCS lipid library which gives information on cholesterol and cholesterol esters with respect to structure, occurrence, biochemistry and analysis)."},{"key":"10.1016\/j.ejmech.2014.08.013_bib178","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/cr.2008.61","article-title":"Feedback regulation of cholesterol synthesis: sterol-accelerated ubiquitination and degradation of HMG CoA reductase","volume":"18","author":"DeBose-Boyd","year":"2008","journal-title":"Cell. Res."},{"issue":"12","key":"10.1016\/j.ejmech.2014.08.013_bib179","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s11745-002-1016-x","article-title":"The role of cytochrome P450 in the regulation of cholesterol biosynthesis","volume":"37","author":"Gibbons","year":"2002","journal-title":"Lipids"},{"key":"10.1016\/j.ejmech.2014.08.013_bib180","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.bmc.2007.10.001","article-title":"Novel cholesterol biosynthesis inhibitors targeting human lanosterol 14-alpha-demethylase (CYP51)","volume":"16","author":"Koro\u0161ec","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2014.08.013_bib181","unstructured":"Website: http:\/\/www.rcsb.org\/pdb\/explore\/explore.do?structureId=3juv (The RCSB PDB provides a variety of tools and resources for studying the structures of biological macromolecules and their relationships to sequence, function, and disease. This site gives the information on the PDB files of the molecular targets for docking experiments)."},{"key":"10.1016\/j.ejmech.2014.08.013_bib182","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1161\/01.RES.88.3.268","article-title":"LDL downregulates CYP51 in porcine vascular endothelial cells and in the arterial wall through a sterol regulatory element binding protein-2-dependent mechanism","volume":"88","author":"Rodr\u00edguez","year":"2001","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejmech.2014.08.013_bib183","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/nar\/11.5.1475","article-title":"Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei","volume":"11","author":"Dignam","year":"1983","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2014.08.013_bib184","unstructured":"Website: http:\/\/www.medscape.org\/viewarticle\/416521_13 (M.H. Davidson, T.A. Jacobson have explained the mechanism of action of the most popular and most effective of the \u201ccholesterol-blocking\u201d medicines, statins, as the HMG CoA reductase inhibitors)."},{"issue":"6","key":"10.1016\/j.ejmech.2014.08.013_bib185","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4254\/wjh.v4.i6.184","article-title":"Regulation and deregulation of cholesterol homeostasis: the liver as a metabolic \u201cpower station\u201d","volume":"4","author":"Trapani","year":"2012","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.ejmech.2014.08.013_bib186","unstructured":"Website: http:\/\/www.trackyourplaque.com\/forum\/topics.aspx?ID=14377 (This website belongs to \u201ctrack your plaque\u201d, which discusses on topics to cure heart diseases)."},{"issue":"47","key":"10.1016\/j.ejmech.2014.08.013_bib187","doi-asserted-by":"crossref","first-page":"16442","DOI":"10.1073\/pnas.0405809101","article-title":"3-Hydroxy-3-methylglutaryl-CoA synthase intermediate complex observed in \u201creal-time\u201d","volume":"101","author":"Theisen","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"47","key":"10.1016\/j.ejmech.2014.08.013_bib188","doi-asserted-by":"crossref","first-page":"16399","DOI":"10.1073\/pnas.0407418101","article-title":"An atomic-resolution mechanism of 3-hydroxy-3-methylglutaryl-CoA synthase","volume":"101","author":"Bahnson","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2014.08.013_bib189","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1023\/A:1010913621768","article-title":"The reversal of the inhibition on lipids synthesis by L-659,699 in arterial smooth muscle cells cultures","volume":"221","author":"Carazo","year":"2001","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.ejmech.2014.08.013_bib190","series-title":"Beta-lactams as anticholesterolemic agents","author":"Yang","year":"1991"},{"issue":"2","key":"10.1016\/j.ejmech.2014.08.013_bib191","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1006\/bbrc.1999.1712","article-title":"Differential inhibition of HMG-CoA synthase and pancreatic lipase by the specific chiral isomers of beta-lactone DU-6622","volume":"265","author":"Tomoda","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2014.08.013_bib192","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1042\/bj2620159","article-title":"Treatment of rats with glucagon or mannoheptulose increases mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase activity and decreases succinyl-CoA content in liver","volume":"262","author":"Quant","year":"1989","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2014.08.013_bib193","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0022-2275(20)32332-4","article-title":"Impaired hepatic fatty acid oxidation in rats with short-term cholestasis: characterization and mechanism","volume":"42","author":"Lang","year":"2001","journal-title":"J.\u00a0Lipid Res."},{"issue":"11","key":"10.1016\/j.ejmech.2014.08.013_bib194","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/iub.522","article-title":"Potential role of nonstatin cholesterol lowering agents","volume":"63","author":"Trapani","year":"2011","journal-title":"IUBMB Life"},{"key":"10.1016\/j.ejmech.2014.08.013_bib195","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1161\/CIRCULATIONAHA.111.028571","article-title":"Squalene synthase inhibitor lapaquistat acetate: could anything be better than statins?","volume":"123","author":"Liao","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ejmech.2014.08.013_bib196a","series-title":"XII International Symposium on Drugs Affecting Lipid Metabolism (Houston, TX, November 7\u201310)","first-page":"54","author":"Harrity","year":"1995"},{"key":"10.1016\/j.ejmech.2014.08.013_bib196b","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1177\/009127009803801205","article-title":"Clinical pharmacokinetics and pharmacodynamics of a new squalene synthase inhibitor, BMS-188494, in healthy volunteers","volume":"38","author":"Sharma","year":"1998","journal-title":"J.\u00a0Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2014.08.013_bib197","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0022-3565(24)36653-4","article-title":"RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase","volume":"281","author":"Amin","year":"1997","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"issue":"18","key":"10.1016\/j.ejmech.2014.08.013_bib198","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1161\/CIRCULATIONAHA.110.975284","article-title":"Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia","volume":"123","author":"Stein","year":"2011","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ejmech.2014.08.013_bib199","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/bjp.2008.143","article-title":"Lapaquistat acetate, a squalene synthase inhibitor, changes macrophage\/lipid-rich coronary plaques of hypercholesterolaemic rabbits into fibrous lesions","volume":"154","author":"Shiomi","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2014.08.013_bib200a","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/S0022-2275(20)32020-4","article-title":"Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: comparison with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors","volume":"41","author":"Hiyoshi","year":"2000","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ejmech.2014.08.013_bib200b","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1194\/jlr.M200316-JLR200","article-title":"Squalene synthase inhibitors suppress triglyceride biosynthesis through the farnesol pathway in rat hepatocytes","volume":"44","author":"Hiyoshi","year":"2003","journal-title":"J.\u00a0Lipid Res."},{"issue":"3","key":"10.1016\/j.ejmech.2014.08.013_bib201","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1124\/jpet.107.126375","article-title":"EP2306 [2-(4-biphenyl)-4-methyloctahydro-1,4-benzoxazin-2-ol, hydrobromide], a novel squalene synthase inhibitor, reduces atherosclerosis in the cholesterol-fed rabbit","volume":"323","author":"Tavridou","year":"2007","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejmech.2014.08.013_bib202","doi-asserted-by":"crossref","first-page":"18750","DOI":"10.1074\/jbc.M112.351254","article-title":"Binding modes of zaragozic acid A to human squalene synthase and staphylococcal dehydrosqualene synthase","volume":"287","author":"Liu","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2014.08.013_bib203","doi-asserted-by":"crossref","first-page":"30610","DOI":"10.1074\/jbc.M004132200","article-title":"Crystal structure of human squalene synthase. A key enzyme in cholesterol biosynthesis","volume":"275","author":"Pandit","year":"2000","journal-title":"J.\u00a0Biol. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2014.08.013_bib204","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1194\/jlr.M016089","article-title":"A\u00a0novel bisphosphonate inhibitor of squalene synthase combined with a statin or a nitrogenous bisphosphonate in\u00a0vitro","volume":"52","author":"Wasko","year":"2011","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ejmech.2014.08.013_bib205","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1139\/o59-099","article-title":"A\u00a0rapid method of total lipid extraction and purification","volume":"37","author":"Bligh","year":"1959","journal-title":"Can. J. Biochem. Physiol."},{"key":"10.1016\/j.ejmech.2014.08.013_bib206","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1096\/fj.06-6368fje","article-title":"Regulation of hepatic cholesterol synthesis by a novel protein (SPF) that accelerates cholesterol biosynthesis","volume":"20","author":"Shibata","year":"2006","journal-title":"FASEB J."},{"key":"10.1016\/j.ejmech.2014.08.013_bib207","doi-asserted-by":"crossref","first-page":"8053","DOI":"10.1074\/jbc.271.14.8053","article-title":"Transcriptional regulation of squalene epoxidase by sterols and inhibitors in HeLa cells","volume":"271","author":"Nakamura","year":"1996","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2014.08.013_bib208","unstructured":"Website: http:\/\/www.uky.edu\/Pharmacy\/ps\/porter\/squalene_mono-oxygenase- biology.htm (This site gives information on biology of squalene monooxygenase)."},{"key":"10.1016\/j.ejmech.2014.08.013_bib209","first-page":"136448","article-title":"US 5011859, 1991, Di-and tetra-fluoro analogs of squalene as inhibitors of squalene epoxidase","volume":"115","author":"Jarvi","year":"1991","journal-title":"Chem. Abstr."},{"key":"10.1016\/j.ejmech.2014.08.013_bib210","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1006\/bbrc.2000.2217","article-title":"Green tea polyphenols: novel and potent inhibitors of squalene epoxidase","volume":"268","author":"Abe","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2014.08.013_bib211","first-page":"1045","article-title":"Absorption, distribution, elimination of tea polyphenols in rats","volume":"25","author":"Chen","year":"1997","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2014.08.013_bib212","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1055\/s-2000-9781","article-title":"Galloyl esters from rhubarb are potent inhibitors of squalene epoxidase, a key enzyme in cholesterol biosynthesis","volume":"66","author":"Abe","year":"2000","journal-title":"Planta. Med."},{"key":"10.1016\/j.ejmech.2014.08.013_bib213","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-2275(20)31684-9","article-title":"Inhibition of human squalene monooxygenase by tellurium compounds: evidence of interaction with vicinal sulfhydryls","volume":"42","author":"Laden","year":"2001","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ejmech.2014.08.013_bib214","unstructured":"Website: http:\/\/www.chembio.uoguelph.ca\/educmat\/chm452\/lectur17.htm (This site gives information on sterol synthesis: squalene to cholesterol)."},{"key":"10.1016\/j.ejmech.2014.08.013_bib215","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/0003-9861(72)90054-9","article-title":"3-Hydroxysterol synthesis by the liver","volume":"150","author":"Brunengraber","year":"1972","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejmech.2014.08.013_bib216a","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0014-5793(72)80266-7","article-title":"Inhibition of cholesterol synthesis by (-)-hydroxycitrate in perfused rat liver. Evidence for an extramitochondrial mevalonate synthesis from acetyl coenzyme A","volume":"22","author":"Barth","year":"1972","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejmech.2014.08.013_bib216b","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0021-9258(18)62460-3","article-title":"Effect of (\u2013)-hydroxycitrate on fatty acid synthesis by rat liver in\u00a0vivo","volume":"246","author":"Lowenstein","year":"1971","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2014.08.013_bib217","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.ejmech.2013.03.002","article-title":"Aminopropylindenes derived from Grundmann's ketone as a novel chemotype of oxidosqualene cyclase inhibitors","volume":"63","author":"Lange","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2014.08.013_bib218","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature02993","article-title":"Insight into steroid scaffold formation from the structure of human oxidosqualene cyclase","volume":"432","author":"Thoma","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2014.08.013_bib219","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1124\/mol.65.5.1302","article-title":"Induction of CYP3A by 2,3-oxidosqualene: lanosterol cyclase inhibitors is mediated by an endogenous squalene metabolite in primary cultured rat hepatocytes","volume":"65","author":"Shenoy","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2014.08.013_bib220","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1126\/science.284.5415.757","article-title":"Orphan nuclear receptors: shifting endocrinology into reverse","volume":"284","author":"Kliewer","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2014.08.013_bib221","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/0092-8674(95)90200-7","article-title":"The RXR heterodimers and orphan receptors","volume":"83","author":"Mangelsdorf","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2014.08.013_bib222","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.abb.2004.09.019","article-title":"Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism","volume":"433","author":"Eloranta","year":"2005","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejmech.2014.08.013_bib223","doi-asserted-by":"crossref","first-page":"5383","DOI":"10.1021\/jm0582221","article-title":"Farnesoid X receptor: from structure to potential clinical applications","volume":"48","author":"Pellicciari","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.08.013_bib224","doi-asserted-by":"crossref","first-page":"10638","DOI":"10.1074\/jbc.275.14.10638","article-title":"Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor","volume":"275","author":"Laffitte","year":"2000","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2014.08.013_bib225","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","article-title":"Bile acids: natural ligands for an orphan nuclear receptor","volume":"284","author":"Parks","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2014.08.013_bib226","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00041433-199906000-00009","article-title":"Bile acids and lipoprotein metabolism: a renaissance for bile acids in the post-statin era?","volume":"10","author":"Angelin","year":"1999","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.ejmech.2014.08.013_bib227","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1126\/science.1072891","article-title":"A\u00a0natural product that lowers cholesterol as an antagonist ligand for FXR","volume":"31","author":"Urizar","year":"2002","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.ejmech.2014.08.013_bib228","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1093\/jn\/131.10.2603","article-title":"Molecular mechanisms of sterol absorption","volume":"131","author":"Chen","year":"2001","journal-title":"J.\u00a0Nutr."},{"key":"10.1016\/j.ejmech.2014.08.013_bib229","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1074\/jbc.M109.083899","article-title":"Identification of novel pathways that control farnesoid X receptor-mediated hypocholesterolemia","volume":"285","author":"Zhang","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2014.08.013_bib230","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1021\/jm8014124","article-title":"Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR)","volume":"52","author":"Flatt","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.08.013_bib231","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1194\/jlr.M800619-JLR200","article-title":"Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR\u2212\/\u2212 and apoE\u2212\/\u2212 mice","volume":"50","author":"Hartman","year":"2009","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ejmech.2014.08.013_bib232","doi-asserted-by":"crossref","first-page":"H272","DOI":"10.1152\/ajpheart.01075.2008","article-title":"Antiatherosclerotic effect of farnesoid X receptor","volume":"296","author":"Mencarelli","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ejmech.2014.08.013_bib233","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1194\/jlr.M015859","article-title":"Aldo-keto reductase 1B7 is a target gene of FXR and regulates lipid and glucose homeostasis","volume":"52","author":"Ge","year":"2011","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ejmech.2014.08.013_bib234a","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/39645","article-title":"Molecular basis of agonism and antagonism in the oestrogen receptor","volume":"389","author":"Brzozowski","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2014.08.013_bib234b","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S1097-2765(03)00133-3","article-title":"Nuclear receptor ligands and cofactor recruitment. Is there a coactivator \u201cOn Deck\u201d?","volume":"11","author":"Nettles","year":"2003","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2014.08.013_bib235","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S1097-2765(03)00104-7","article-title":"A\u00a0chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR","volume":"11","author":"Downes","year":"2003","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2014.08.013_bib236","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S1097-2765(03)00112-6","article-title":"Structural basis for bile acid binding and activation of the nuclear receptor FXR","volume":"11","author":"Mi","year":"2003","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2014.08.013_bib237","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0955-0674(97)80066-X","article-title":"Nuclear receptor coactivators","volume":"9","author":"Glass","year":"1997","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.ejmech.2014.08.013_bib238","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.5012\/bkcs.2011.32.12.4165","article-title":"Synthesis of an unnatural steroid as a farnesoid X receptor antagonist","volume":"32","author":"Park","year":"2011","journal-title":"Bull. Korean Chem. Soc."},{"issue":"5","key":"10.1016\/j.ejmech.2014.08.013_bib239","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1021\/jm101336m","article-title":"Discovery of sulfated sterols from marine invertebrates as a new class of marine natural antagonists of farnesoid-X-receptor","volume":"54","author":"Sepe","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2014.08.013_bib240","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.numecd.2011.06.008","article-title":"FXR activation improves myocardial fatty acid metabolism in a rodent model of obesity-driven cardiotoxicity","volume":"23","author":"Mencarelli","year":"2013","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"10","key":"10.1016\/j.ejmech.2014.08.013_bib241","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1073\/pnas.0400046101","article-title":"Expression and activation of the farnesoid X receptor in the vasculature","volume":"101","author":"Bailey","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2014.08.013_bib242","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1172\/JCI0215593","article-title":"SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver","volume":"109","author":"Horton","year":"2002","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ejmech.2014.08.013_bib243","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0083-6729(02)65064-2","article-title":"Sterol regulatory element-binding protein family as global regulators of lipid synthetic genes in energy metabolism","volume":"65","author":"Shimano","year":"2002","journal-title":"Vitam. Horm."},{"key":"10.1016\/j.ejmech.2014.08.013_bib244","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1073\/pnas.0130116100","article-title":"Liver-specific mRNA for insig-2 down-regulated by insulin: implications for fatty acid synthesis","volume":"100","author":"Yabe","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2014.08.013_bib245","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1101\/gad.1854309","article-title":"Evolutionary conservation and adaptation in the mechanism that regulates SREBP action: what a long, strange tRIP it's been","volume":"23","author":"Osborne","year":"2009","journal-title":"Gene. Dev."},{"key":"10.1016\/j.ejmech.2014.08.013_bib246","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nrm1174","article-title":"The SREBP pathway-insights from insigs and insects","volume":"4","author":"Rawson","year":"2003","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"3","key":"10.1016\/j.ejmech.2014.08.013_bib247","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cmet.2011.02.004","article-title":"Regulation of lipid homeostasis by the bifunctional SREBF2-miR33a locus","volume":"13","author":"Bommer","year":"2011","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejmech.2014.08.013_bib248a","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/nm1201-1332","article-title":"SCAP ligands are potent new lipid-lowering drugs","volume":"7","author":"Grand-Perret","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2014.08.013_bib248b","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/nm1201-1282","article-title":"A\u00a0new feature on the cholesterol-lowering landscape","volume":"7","author":"Rader","year":"2001","journal-title":"Nat. Med."},{"issue":"40","key":"10.1016\/j.ejmech.2014.08.013_bib249","doi-asserted-by":"crossref","first-page":"17321","DOI":"10.1073\/pnas.1008499107","article-title":"MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in\u00a0vivo","volume":"107","author":"Horie","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2014.08.013_bib250","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1126\/science.1189123","article-title":"MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis","volume":"328","author":"Shoushtari","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2014.08.013_bib251","doi-asserted-by":"crossref","first-page":"E918","DOI":"10.1152\/ajpendo.00376.2010","article-title":"Sterol regulatory element binding protein and dietary lipid regulation of fatty acid synthesis in the mammary epithelium","volume":"299","author":"Rudolph","year":"2010","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"15","key":"10.1016\/j.ejmech.2014.08.013_bib252","doi-asserted-by":"crossref","first-page":"11681","DOI":"10.1074\/jbc.M109.096107","article-title":"Polyunsaturated fatty acids selectively suppress sterol regulatory element-binding protein-1 through proteolytic processing and autoloop regulatory circuit","volume":"285","author":"Takeuchi","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"issue":"44","key":"10.1016\/j.ejmech.2014.08.013_bib253","doi-asserted-by":"crossref","first-page":"27879","DOI":"10.1074\/jbc.271.44.27879","article-title":"Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase","volume":"271","author":"Hawley","year":"1996","journal-title":"J.\u00a0Biol. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2014.08.013_bib254","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.cmet.2011.03.009","article-title":"AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice","volume":"13","author":"Li","year":"2011","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejmech.2014.08.013_bib255","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.cell.2011.06.034","article-title":"mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway","volume":"146","author":"Peterson","year":"2011","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ejmech.2014.08.013_bib256","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cmet.2010.12.004","article-title":"Inhibition of SREBP by a small molecule, betulin, improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques","volume":"13","author":"Tang","year":"2011","journal-title":"Cell Metab."},{"issue":"5","key":"10.1016\/j.ejmech.2014.08.013_bib257","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.tem.2010.01.001","article-title":"The Akt-SREBP nexus: cell signaling meets lipid metabolism","volume":"21","author":"Krycer","year":"2010","journal-title":"Trends Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.ejmech.2014.08.013_bib258","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.atherosclerosis.2012.12.021","article-title":"Lipopolysaccharide downregulates CD91\/low-density lipoprotein receptor-related protein 1 expression through SREBP-1 overexpression in human macrophages","volume":"227","author":"Costales","year":"2013","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.ejmech.2014.08.013_bib259","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000350751","article-title":"Analysis of sterol-regulatory element-binding protein 1c target genes in mouse liver during aging and high-fat diet","volume":"6","author":"Capel","year":"2013","journal-title":"J.\u00a0Nutrigenet. Nutrigenomics"},{"issue":"4","key":"10.1016\/j.ejmech.2014.08.013_bib260","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.cmet.2012.09.002","article-title":"Expanding roles for SREBP in metabolism","volume":"16","author":"Shao","year":"2012","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.ejmech.2014.08.013_bib261","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.tem.2011.10.004","article-title":"SREBPs: metabolic integrators in physiology and metabolism","volume":"23","author":"Jeon","year":"2012","journal-title":"Trends Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.ejmech.2014.08.013_bib262","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3724\/SP.J.1005.2013.00607","article-title":"Sterol regulatory element binding protein 1 and its target gene networks","volume":"35","author":"Tang","year":"2013","journal-title":"Yi Chuan"},{"key":"10.1016\/j.ejmech.2014.08.013_bib263","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0969-2126(98)00067-7","article-title":"Co-crystal structure of sterol regulatory element binding protein 1a at 2.3 \u00c5 resolution","volume":"6","author":"Parraga","year":"1998","journal-title":"Structure"},{"issue":"Suppl.\u00a0l","key":"10.1016\/j.ejmech.2014.08.013_bib264","first-page":"1","volume":"13","author":"Tang","year":"2011","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejmech.2014.08.013_bib265","doi-asserted-by":"crossref","first-page":"9094","DOI":"10.1016\/S0021-9258(18)81907-X","article-title":"Glycosylation of human apolipoprotein E. The carbohydrate attachment site is threonine 194","volume":"264","author":"Wernette-Hammond","year":"1989","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2014.08.013_bib266","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1126\/science.3283935","article-title":"Apolipoprotein E: cholesterol transport protein with expanding role in cell biology","volume":"240","author":"Mahley","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2014.08.013_bib267","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2796.1992.tb01254.x","article-title":"The role of apolipoprotein E genetic variants in lipoprotein disorders","volume":"231","author":"Rall","year":"1992","journal-title":"J.\u00a0Intern. Med."},{"key":"10.1016\/j.ejmech.2014.08.013_bib268","doi-asserted-by":"crossref","first-page":"9077","DOI":"10.1016\/S0021-9258(19)52510-8","article-title":"Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms","volume":"256","author":"Rall","year":"1981","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2014.08.013_bib269","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11745-000-0500-7","article-title":"Apolipoprotein E polymorphism: automated determination of apolipoprotein E2, E3, and E4 isoforms","volume":"35","author":"Wiebe","year":"2000","journal-title":"Lipids"},{"key":"10.1016\/j.ejmech.2014.08.013_bib270","unstructured":"Website: http:\/\/lipidlibrary.aocs.org\/Lipids\/lipoprot\/index.htm (This homepage gives information on composition, structure and metabolism of plasma lipoproteins)."},{"key":"10.1016\/j.ejmech.2014.08.013_bib271","doi-asserted-by":"crossref","first-page":"R1323","DOI":"10.1152\/ajpregu.00249.2013","article-title":"Mas receptor deficiency is associated with worsening of lipid profile and severe hepatic steatosis in ApoE-knockout mice","volume":"305","author":"Silva","year":"2013","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"issue":"5","key":"10.1016\/j.ejmech.2014.08.013_bib272","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.celrep.2012.09.018","article-title":"Cardiovascular protection by ApoE and ApoE-HDL linked to suppression of ECM gene expression and arterial stiffening","volume":"2","author":"Kothapalli","year":"2012","journal-title":"Cell. Rep."},{"key":"10.1016\/j.ejmech.2014.08.013_bib273","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1476-511X-12-43","article-title":"Plasma levels of apolipoprotein-E in residents of the European North of Russia","volume":"12","author":"Kaneva","year":"2013","journal-title":"Lipids Health Dis."},{"issue":"2","key":"10.1016\/j.ejmech.2014.08.013_bib274","doi-asserted-by":"crossref","first-page":"e57571","DOI":"10.1371\/journal.pone.0057571","article-title":"VPO1 mediates ApoE oxidation and impairs the clearance of plasma lipids","volume":"8","author":"Yang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2014.08.013_bib275","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1194\/jlr.M031906","article-title":"ApoE derived from adipose tissue does not suppress atherosclerosis or correct hyperlipidemia in apoE knockout mice","volume":"54","author":"Huang","year":"2013","journal-title":"J.\u00a0Lipid Res."},{"issue":"4","key":"10.1016\/j.ejmech.2014.08.013_bib276","first-page":"1","article-title":"Structural and functional characterization of human apolipoprotein E 72-166 peptides in both aqueous and lipid environments","volume":"18","author":"Hsieh","year":"2011","journal-title":"J.\u00a0Biomed. Sci."},{"issue":"3","key":"10.1016\/j.ejmech.2014.08.013_bib277","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2014.08.013_bib278","unstructured":"Website: http:\/\/www.nytimes.com\/2013\/07\/10\/health\/rare-mutation-prompts-race-for-cholesterol-drug.html?_r=0&adxnnl=1&adxnnlx=1381876522-n6gnLA2aP-9bW5N-TQ3f\u00a0+ pMA (G. Kolata (July 9, 2013). New York Times. This article describes new approaches to heart disease.)."},{"key":"10.1016\/j.ejmech.2014.08.013_bib279","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.tibs.2006.12.008","article-title":"Molecular biology of PCSK9: its role in LDL metabolism","volume":"32","author":"Horton","year":"2007","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejmech.2014.08.013_bib280","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: a convertase that coordinates LDL catabolism","volume":"50","author":"Horton","year":"2009","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ejmech.2014.08.013_bib281","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1210\/jc.2009-0141","article-title":"Genetic and metabolic determinants of plasma PCSK9 levels","volume":"94","author":"Lakoski","year":"2009","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2014.08.013_bib282","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2014.08.013_bib283","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2014.08.013_bib284","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ejmech.2014.08.013_bib285","first-page":"1","article-title":"Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly","volume":"8","author":"Holla","year":"2007","journal-title":"BMC Cell. Biol."},{"issue":"11","key":"10.1016\/j.ejmech.2014.08.013_bib286","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1172\/JCI29383","article-title":"Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice","volume":"116","author":"Lagace","year":"2006","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ejmech.2014.08.013_bib287","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2014.08.013_bib288","doi-asserted-by":"crossref","first-page":"30561","DOI":"10.1074\/jbc.M606495200","article-title":"The proprotein convertase PCSK9 is inactivated by furin and\/or PC5\/6A: functional consequences of natural mutations and post-translational modifications","volume":"281","author":"Benjannet","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2014.08.013_bib289","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1086\/507488","article-title":"Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote","volume":"79","author":"Zhao","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ejmech.2014.08.013_bib290","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1073\/pnas.0409736102","article-title":"Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment","volume":"102","author":"Maxwell","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2014.08.013_bib291","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/embor.2011.205","article-title":"Mechanistic implications for LDL receptor degradation from the PCSK9\/LDLR structure at neutral pH","volume":"12","author":"Surdo","year":"2011","journal-title":"EMBO Rep."},{"key":"10.1016\/j.ejmech.2014.08.013_bib292","doi-asserted-by":"crossref","first-page":"9546","DOI":"10.1073\/pnas.0904560106","article-title":"Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels","volume":"106","author":"Steinberg","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2014.08.013_bib293","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1194\/jlr.C600025-JLR200","article-title":"Antisense inhibition of proprotein convertase subtilisin\/kexin type 9 reduces serum LDL in hyperlipidemic mice","volume":"48","author":"Graham","year":"2007","journal-title":"J.\u00a0Lipid Res."},{"issue":"15","key":"10.1016\/j.ejmech.2014.08.013_bib294","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1073\/pnas.0501652102","article-title":"Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9","volume":"102","author":"Rashid","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2014.08.013_bib295","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2013.01.044","article-title":"The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway","volume":"228","author":"Catapano","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejmech.2014.08.013_bib296","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1194\/jlr.M900273-JLR200","article-title":"A\u00a0new method for measurement of total plasma PCSK9: clinical applications","volume":"51","author":"Dubuc","year":"2010","journal-title":"J.\u00a0Lipid Res."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523414007405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523414007405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:05:28Z","timestamp":1746327928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523414007405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":309,"alternative-id":["S0223523414007405"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2014.08.013","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Some molecular targets for antihyperlipidemic drug research","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2014.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}